Research graph
References from Early response toward clinical remission with dupilumab in severe asthma: Real-world cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
Asthma
10.1016/s0140-6736(22)02125-0 · 2023 · External reference
The global impact of asthma in adult populations
10.5334/aogh.2412 · 2019 · External reference
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
10.1183/13993003.00588-2019 · 2020 · External reference
Type 2 inflammation in asthma—present in most, absent in many
10.1038/nri3786 · 2015 · External reference
Increased nitric oxide in exhaled air of asthmatic patients
10.1016/s0140-6736(94)90931-8 · 1994 · External reference
2020 Focused Updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group
10.1016/j.jaci.2020.10.003 · 2020 · External reference
Biologic therapies for severe asthma
10.1056/nejmra2032506 · 2022 · External reference
Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma
10.1056/nejmoa1804092 · 2018 · External reference
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study
10.1164/rccm.201208-1414oc · 2013 · External reference
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
10.1016/s0140-6736(12)60988-x · 2012 · External reference
Tezepelumab in adults and adolescents with severe, uncontrolled asthma
10.1056/nejmoa2034975 · 2021 · External reference
Asthma remission: what is it and how can it be achieved?
10.1183/13993003.02583-2021 · 2022 · External reference
Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment
10.1016/j.anai.2023.08.609 · 2023 · External reference
Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023—published by the German Respiratory Society (DGP) e. V [in German]
2023 · External reference
An expert consensus framework for asthma remission as a treatment goal
10.1016/j.jaci.2019.12.006 · 2020 · External reference
Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma
10.1016/j.jaip.2024.10.009 · 2025 · External reference
Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study
10.1016/j.rmed.2024.107720 · 2024 · External reference
Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study
10.3390/jcm13010291 · 2024 · External reference
Predicting dupilumab effectiveness with type-2 biomarkers: a real-world study of severe asthma
10.1016/j.alit.2024.08.005 · 2025 · External reference
The PHQ-9: validity of a brief depression severity measure
10.1046/j.1525-1497.2001.016009606.x · 2001 · External reference
Development of the asthma control test: a survey for assessing asthma control
10.1016/j.jaci.2003.09.008 · 2004 · External reference
Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects
10.2332/allergolint.10-oa-0277 · 2011 · External reference
Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population
10.2332/allergolint.10-oa-0197 · 2010 · External reference
An official JRS statement: the principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice
10.1016/j.resinv.2020.05.006 · 2021 · External reference
Unresolved reference
2024 · External reference
Immunoglobulin E levels and pregnancy-induced hypertension: Japan Environment and Children’s Study
10.1038/s41598-021-88227-2 · 2021 · External reference
Clinical asthma remission obtained with biologics in real life: patients’ prevalence and characteristics
10.3390/jpm13061020 · 2023 · External reference
Clinical response and remission in patients with severe asthma treated with biologic therapies
10.1016/j.chest.2023.10.046 · 2024 · External reference
The relationship of asthma biologics to remission for asthma
10.1016/j.jaip.2020.10.035 · 2021 · External reference
A review on the pathophysiology of asthma remission
10.1016/j.pharmthera.2019.05.002 · 2019 · External reference
Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus
10.1016/j.jaip.2023.07.041 · 2023 · External reference
Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion
10.1016/j.jaip.2021.10.059 · 2022 · External reference
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma
10.1056/nejmoa1403291 · 2014 · External reference
Oral glucocorticoid-sparing effect of benralizumab in severe asthma
10.1056/nejmoa1703501 · 2017 · External reference
Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma
10.1056/nejmoa1804093 · 2018 · External reference
How can we minimise the use of regular oral corticosteroids in asthma?
10.1183/16000617.0085-2019 · 2020 · External reference
Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways
10.1080/02770903.2019.1705335 · 2021 · External reference
Systematic literature review of systemic corticosteroid use for asthma management
10.1164/rccm.201904-0903so · 2020 · External reference
Early treatment response to mepolizumab predicts clinical remission in severe eosinophilic asthma
10.1016/j.jaip.2024.10.041 · 2025 · External reference
Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy
10.1016/j.alit.2022.11.008 · 2023 · External reference
